» Articles » PMID: 38576426

SARS-CoV-2 Infection of Endothelial Cells, Dependent on Flow-induced ACE2 Expression, Drives Hypercytokinemia in a Vascularized Microphysiological System

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for COVID-19, has caused nearly 7 million deaths worldwide. Severe cases are marked by an aggressive inflammatory response known as hypercytokinemia, contributing to endothelial damage. Although vaccination has reduced hospitalizations, hypercytokinemia persists in breakthrough infections, emphasizing the need for disease models mimicking this response. Using a 3D microphysiological system (MPS), we explored the vascular role in SARS-CoV-2-induced hypercytokinemia.

Methods: The vascularized micro-organ (VMO) MPS, consisting of human-derived primary endothelial cells (ECs) and stromal cells within an extracellular matrix, was used to model SARS-CoV-2 infection. A non-replicative pseudotyped virus fused to GFP was employed, allowing visualization of viral entry into human ECs under physiologic flow conditions. Expression of ACE2, TMPRSS2, and AGTR1 was analyzed, and the impact of viral infection on ACE2 expression, vascular inflammation, and vascular morphology was assessed.

Results: The VMO platform facilitated the study of COVID-19 vasculature infection, revealing that ACE2 expression increased significantly in direct response to shear stress, thereby enhancing susceptibility to infection by pseudotyped SARS-CoV-2. Infected ECs secreted pro-inflammatory cytokines, including IL-6 along with coagulation factors. Cytokines released by infected cells were able to activate downstream, non-infected EC, providing an amplification mechanism for inflammation and coagulopathy.

Discussion: Our findings highlight the crucial role of vasculature in COVID-19 pathogenesis, emphasizing the significance of flow-induced ACE2 expression and subsequent inflammatory responses. The VMO provides a valuable tool for studying SARS-CoV-2 infection dynamics and evaluating potential therapeutics.

Citing Articles

The Interplay Between Immunity, Inflammation and Endothelial Dysfunction.

Chee Y, Dalan R, Cheung C Int J Mol Sci. 2025; 26(4).

PMID: 40004172 PMC: 11855323. DOI: 10.3390/ijms26041708.


Capturing physiological hemodynamic flow and mechanosensitive cell signaling in vessel-on-a-chip platforms.

Martier A, Chen Z, Schaps H, Mondrinos M, Fang J Front Physiol. 2024; 15:1425618.

PMID: 39135710 PMC: 11317428. DOI: 10.3389/fphys.2024.1425618.


Protein C Pretreatment Protects Endothelial Cells from SARS-CoV-2-Induced Activation.

Silva B, Sidarta-Oliveira D, Morari J, Bombassaro B, Jara C, Simeoni C Viruses. 2024; 16(7).

PMID: 39066212 PMC: 11281670. DOI: 10.3390/v16071049.


Pathogenic mechanisms of cardiovascular damage in COVID-19.

Shao H, Yin R Mol Med. 2024; 30(1):92.

PMID: 38898389 PMC: 11186295. DOI: 10.1186/s10020-024-00855-2.

References
1.
Gao H, Liu L, Zhao Y, Hara H, Chen P, Xu J . Human IL-6, IL-17, IL-1β, and TNF-α differently regulate the expression of pro-inflammatory related genes, tissue factor, and swine leukocyte antigen class I in porcine aortic endothelial cells. Xenotransplantation. 2017; 24(2). DOI: 10.1111/xen.12291. View

2.
Potus F, Mai V, Lebret M, Malenfant S, Breton-Gagnon E, Lajoie A . Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol Lung Cell Mol Physiol. 2020; 319(2):L277-L288. PMC: 7414237. DOI: 10.1152/ajplung.00195.2020. View

3.
L Moya M, Hsu Y, Lee A, Hughes C, George S . In vitro perfused human capillary networks. Tissue Eng Part C Methods. 2013; 19(9):730-7. PMC: 3719485. DOI: 10.1089/ten.TEC.2012.0430. View

4.
Sobrino A, Phan D, Datta R, Wang X, Hachey S, Romero-Lopez M . 3D microtumors in vitro supported by perfused vascular networks. Sci Rep. 2016; 6:31589. PMC: 4994029. DOI: 10.1038/srep31589. View

5.
Melero-Martin J, De Obaldia M, Kang S, Khan Z, Yuan L, Oettgen P . Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res. 2008; 103(2):194-202. PMC: 2746761. DOI: 10.1161/CIRCRESAHA.108.178590. View